Amgen price hikes to offset Aranesp payment drop

A new Medicare payment scheme for dialysis will likely result in a revenue drop for Amgen from its kidney disease treatment Aranesp. To compensate, the drugmaker has raised prices on several drugs.

Aranesp itself gets a 4.4 percent boost, reports Bloomberg. Prices on chemo-effect treatments Neulasta and Neupogen jump 2.9 percent.

Medicare cost controls have yielded a new payment scheme for dialysis treatment. In addition, Amgen suffered a 15 percent drop in sales of Aranesp in 2009, according to the report.

- here's the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.